|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHX30 |
Gene summary for DHX30 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHX30 | Gene ID | 22907 |
| Gene name | DExH-box helicase 30 | |
| Gene Alias | DDX30 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000027 | UniProtAcc | H7BXY3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22907 | DHX30 | LZE2T | Human | Esophagus | ESCC | 1.34e-06 | 6.62e-01 | 0.082 |
| 22907 | DHX30 | LZE4T | Human | Esophagus | ESCC | 1.56e-08 | 2.91e-01 | 0.0811 |
| 22907 | DHX30 | LZE5T | Human | Esophagus | ESCC | 4.67e-02 | 2.73e-01 | 0.0514 |
| 22907 | DHX30 | LZE7T | Human | Esophagus | ESCC | 3.87e-05 | 4.62e-01 | 0.0667 |
| 22907 | DHX30 | LZE24T | Human | Esophagus | ESCC | 2.27e-11 | 2.99e-01 | 0.0596 |
| 22907 | DHX30 | P1T-E | Human | Esophagus | ESCC | 1.18e-03 | 3.94e-01 | 0.0875 |
| 22907 | DHX30 | P2T-E | Human | Esophagus | ESCC | 1.10e-26 | 4.18e-01 | 0.1177 |
| 22907 | DHX30 | P4T-E | Human | Esophagus | ESCC | 1.59e-18 | 4.94e-01 | 0.1323 |
| 22907 | DHX30 | P5T-E | Human | Esophagus | ESCC | 5.19e-17 | 2.27e-01 | 0.1327 |
| 22907 | DHX30 | P8T-E | Human | Esophagus | ESCC | 4.76e-22 | 4.39e-01 | 0.0889 |
| 22907 | DHX30 | P9T-E | Human | Esophagus | ESCC | 5.05e-17 | 4.41e-01 | 0.1131 |
| 22907 | DHX30 | P10T-E | Human | Esophagus | ESCC | 7.74e-37 | 5.91e-01 | 0.116 |
| 22907 | DHX30 | P11T-E | Human | Esophagus | ESCC | 7.30e-16 | 4.69e-01 | 0.1426 |
| 22907 | DHX30 | P12T-E | Human | Esophagus | ESCC | 1.77e-31 | 7.21e-01 | 0.1122 |
| 22907 | DHX30 | P15T-E | Human | Esophagus | ESCC | 5.62e-21 | 4.10e-01 | 0.1149 |
| 22907 | DHX30 | P16T-E | Human | Esophagus | ESCC | 5.69e-24 | 5.00e-01 | 0.1153 |
| 22907 | DHX30 | P17T-E | Human | Esophagus | ESCC | 3.17e-04 | 4.32e-01 | 0.1278 |
| 22907 | DHX30 | P19T-E | Human | Esophagus | ESCC | 2.73e-09 | 6.75e-01 | 0.1662 |
| 22907 | DHX30 | P20T-E | Human | Esophagus | ESCC | 2.17e-24 | 4.78e-01 | 0.1124 |
| 22907 | DHX30 | P21T-E | Human | Esophagus | ESCC | 9.78e-21 | 4.66e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:0042273111 | Esophagus | ESCC | ribosomal large subunit biogenesis | 65/8552 | 72/18723 | 1.53e-15 | 9.82e-14 | 65 |
| GO:0042255111 | Esophagus | ESCC | ribosome assembly | 50/8552 | 61/18723 | 5.66e-09 | 1.17e-07 | 50 |
| GO:0000027111 | Esophagus | ESCC | ribosomal large subunit assembly | 22/8552 | 27/18723 | 1.49e-04 | 9.92e-04 | 22 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:007182612 | Liver | Cirrhotic | ribonucleoprotein complex subunit organization | 115/4634 | 227/18723 | 2.67e-17 | 3.63e-15 | 115 |
| GO:002261812 | Liver | Cirrhotic | ribonucleoprotein complex assembly | 112/4634 | 220/18723 | 4.35e-17 | 5.81e-15 | 112 |
| GO:004227312 | Liver | Cirrhotic | ribosomal large subunit biogenesis | 47/4634 | 72/18723 | 4.20e-13 | 3.29e-11 | 47 |
| GO:004225512 | Liver | Cirrhotic | ribosome assembly | 39/4634 | 61/18723 | 1.07e-10 | 5.72e-09 | 39 |
| GO:000002712 | Liver | Cirrhotic | ribosomal large subunit assembly | 15/4634 | 27/18723 | 5.96e-04 | 4.63e-03 | 15 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:007182622 | Liver | HCC | ribonucleoprotein complex subunit organization | 159/7958 | 227/18723 | 3.14e-17 | 3.06e-15 | 159 |
| GO:004227322 | Liver | HCC | ribosomal large subunit biogenesis | 64/7958 | 72/18723 | 2.31e-16 | 2.03e-14 | 64 |
| GO:002261822 | Liver | HCC | ribonucleoprotein complex assembly | 153/7958 | 220/18723 | 3.44e-16 | 2.91e-14 | 153 |
| GO:004225522 | Liver | HCC | ribosome assembly | 50/7958 | 61/18723 | 2.79e-10 | 9.50e-09 | 50 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHX30 | SNV | Missense_Mutation | rs748383690 | c.1951N>A | p.Asp651Asn | p.D651N | Q7L2E3 | protein_coding | tolerated(0.19) | benign(0.137) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DHX30 | SNV | Missense_Mutation | rs754158644 | c.2086G>A | p.Glu696Lys | p.E696K | Q7L2E3 | protein_coding | tolerated(0.85) | benign(0.001) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX30 | SNV | Missense_Mutation | rs776820854 | c.2987N>T | p.Ser996Leu | p.S996L | Q7L2E3 | protein_coding | deleterious(0.02) | benign(0.05) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
| DHX30 | insertion | Nonsense_Mutation | novel | c.1843_1844insGAACAAGGACTGAGTAGAACTGGAGGCATCTGAGCTT | p.Met615ArgfsTer6 | p.M615Rfs*6 | Q7L2E3 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DHX30 | insertion | In_Frame_Ins | novel | c.909_910insATTTCATGCCTTCTGCCCTTCTGGCTCCCT | p.Lys303_Ala304insIleSerCysLeuLeuProPheTrpLeuPro | p.K303_A304insISCLLPFWLP | Q7L2E3 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| DHX30 | insertion | Frame_Shift_Ins | novel | c.797_798insCCTCCACA | p.Met266IlefsTer26 | p.M266Ifs*26 | Q7L2E3 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| DHX30 | insertion | Nonsense_Mutation | novel | c.799_800insTAAGGTGAGTTGGGTCTCCTAGA | p.Gln267LeufsTer3 | p.Q267Lfs*3 | Q7L2E3 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| DHX30 | insertion | Frame_Shift_Ins | novel | c.1725_1726insCCTGACCAACATGGTGAAACCTTGTCTGTACTAAAAATACA | p.Lys576ProfsTer29 | p.K576Pfs*29 | Q7L2E3 | protein_coding | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| DHX30 | SNV | Missense_Mutation | rs139889547 | c.464G>A | p.Arg155His | p.R155H | Q7L2E3 | protein_coding | tolerated_low_confidence(0.06) | benign(0.232) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DHX30 | SNV | Missense_Mutation | novel | c.742C>A | p.Leu248Ile | p.L248I | Q7L2E3 | protein_coding | tolerated(0.1) | benign(0.242) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |